An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations
Small Methods · 2026
DOI: 10.1002/smtd.202500945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2026. Verfasst von Julien Santelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Translational Research in Ultrasound Theranostics (TRUST) Program, University of Texas Southwestern Medical Center, Dallas, …. Hauptthemen laut MEDLINE: Asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, American Cancer Society, 2017 DocStars award from the Cary Council (Southwestern Foundation).
Abstract (Originalsprache)
Acute Lymphoblastic Leukemia (ALL) accounts for over 25% of pediatric cancers. It affects lymphoid progenitor cells, leading to overproduction of immature B‐ or T‐cells. ALL cells rely on asparagine for survival. Therefore, the addition of l ‐asparaginase (ASNase), an enzyme that depletes asparagine, to the ALL chemotherapy backbone has dramatically improved treatment outcomes. However, marketed formulations of l ‐ASNase, all derived from bacteria, with or without polyethylene glycol (PEG) modification, cause allergic reactions to the enzyme or to PEG, impacting treatment efficacy. Herein, existing procedures are capitalized on to propose an integrated set of improved methods to evaluate the efficacy of ASNase formulations against B‐cell ALL in mice, comprising the establishment of an ALL murine model not requiring humanization, an amino acid depletion study, and an assessment of antibody production. It is shown that unmodified ASNase results in short‐lived asparagine depletion and a strong immune response. PEG‐ASNase produces longer‐lasting asparagine depletion, reduces ALL cell counts, and minimizes anti‐ASNase immunogenicity but induces an increased immune response to PEG and is not curative without the chemotherapy backbone. With the increasing use of PEG‐modified drugs, these tools offer a framework for assessing pharmacokinetics and immunogenicity of new enzyme‐based therapeutics or nanoparticles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Translational Research in Ultrasound Theranostics (TRUST) Program, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
ORCID-Profile: Julien Santelli, Annie Y Heble, Jacques Lux
Förderung
- Cancer Prevention and Research Institute of Texas
- American Cancer Society
- 2017 DocStars award from the Cary Council (Southwestern Foundation)
- Children's Cancer Fund Comprehensive Center for Pediatric Oncology Research
- NSF GRFP award (National Science FoundationGraduate Research Fellowship Program award to A.Y.H.)
Zitieren
APA
Santelli, J., Heble, A. Y., Endsley, C., Woodward, A., Hafeez, N., Winick, N., & Lux, J. (2026). An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations. Small Methods. https://doi.org/10.1002/smtd.202500945
Vancouver
Santelli J, Heble AY, Endsley C, Woodward A, Hafeez N, Winick N, et al. An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations. Small Methods. 2026. doi:10.1002/smtd.202500945
BibTeX
@article{Santelli2026,
author = {Santelli, Julien and Heble, Annie Y and Endsley, Connor and Woodward, Adam and Hafeez, Nazia and Winick, Naomi and Lux, Jacques},
title = {An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations},
journal = {Small Methods},
year = {2026},
doi = {10.1002/smtd.202500945}
}
EUVIMED